catalogue
1、 Assurance report on the annual deposit and use of raised funds Page 1-2 II. Special report on the annual deposit and use of raised funds……………….. page 3-7
Verification report on annual deposit and use of raised funds
TJS [2022] No. 810
All shareholders of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd.:
We have verified the attached special report on the annual storage and use of raised funds in 2021 prepared by the board of directors of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Baicheng pharmaceutical company).
1、 Restrictions on the users and purposes of the report
This assurance report is only used for the disclosure of the annual report of Baicheng pharmaceutical company and shall not be used for any other purpose. We agree to take this assurance report as a necessary document for the annual report of Baicheng pharmaceutical company, submit it together with other documents and disclose it to the public.
2、 Responsibilities of the board of directors
The responsibility of the board of directors of Baicheng Pharmaceutical Co., Ltd. is to provide true, legal and complete relevant materials, and prepare the special report on the annual deposit and use of raised funds in accordance with the self regulatory guidelines for listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM (SZS [2022] No. 14) and relevant format guidelines, And ensure that its contents are true, accurate and complete, and there are no false records, misleading statements or major omissions.
3、 Responsibilities of Certified Public Accountants
Our responsibility is to independently put forward the assurance conclusion of the above report prepared by the board of directors of Baicheng pharmaceutical company on the basis of the implementation of the assurance work.
4、 Job overview
We have carried out the assurance business in accordance with the provisions of the practice standards of Chinese certified public accountants. The Chinese CPA practice standards require us to plan and implement the assurance work to obtain reasonable assurance about whether the information of the assurance object is free from material misstatement. In the assurance process, we have implemented procedures that we consider necessary, including checking accounting records. We believe that our assurance work provides a reasonable basis for expressing opinions.
5、 Assurance conclusion
We believe that the 2021 special report on the annual deposit and use of raised funds prepared by the board of directors of Baicheng Pharmaceutical Co., Ltd. complies with the provisions of self regulatory guidelines for listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM (SZS [2022] No. 14) and relevant format guidelines, It truthfully reflects the actual storage and use of the funds raised by Baicheng pharmaceutical company in 2021. Tianjian Certified Public Accountants (special general partnership) Chinese certified public accountant:
Hangzhou, China Certified Public Accountant:
March 13, 2002
Hangzhou Baicheng Pharmaceutical Technology Co., Ltd
Special report on the annual storage and use of raised funds
According to the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies (SZS [2022] No. 14) and relevant format guidelines issued by Shenzhen Stock Exchange, the deposit and use of the company’s raised funds in 2021 are specially explained as follows.
1、 Basic information of raised funds
（1） Actual amount of raised funds and time of fund arrival
According to the reply on Approving the registration of initial public offering of shares of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (zjxk [2021] No. 3566) issued by China Securities Regulatory Commission, the company’s lead underwriter Sinolink Securities Co.Ltd(600109) Co., Ltd. publicly issued 27041667 RMB common shares (A shares) to the public, The issue price is 79.60 yuan per share, with a total raised capital of 215251669320 yuan. The raised capital after deducting the underwriting and recommendation expenses of 26187750398 yuan is 189063918922 yuan, which has been remitted to the raised capital supervision account of the company by the lead underwriter Sinolink Securities Co.Ltd(600109) joint stock company on December 15, 2021. In addition, after deducting 2720910081 yuan of additional external expenses directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, reporting accountant fee, lawyer fee and evaluation fee, the net amount of funds raised by the company this time is 18634 Dnake (Xiamen) Intelligent Technology Co.Ltd(300884) 1 yuan. The availability of the above-mentioned raised funds has been verified by Tianjian Certified Public Accountants (special general partnership), who issued the capital verification report (Tianjian Yan [2021] No. 738).
（2） Use and balance of raised funds
Monetary unit: RMB
Item No. amount
Net amount of raised funds a 18634 Dnake (Xiamen) Intelligent Technology Co.Ltd(300884) 1
Project input B1
Accumulated amount as of the beginning of the period
Net interest income B2
Project input C1
Net interest income incurred in the current period
C2 67985114
Item No. amount
Project input D1 = B1 + C1
Accumulated amount by the end of the period
Net interest income D2 = B2 + C267985114
The balance of funds raised should be e = a-d1 + D2186410993955
Actual balance of raised funds f 188831904036
Difference [note] g = E-F -2420910081
[note] the difference refers to the unpaid external expenses directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, reporting accountant fee, lawyer fee, evaluation fee and so on
2、 Deposit and management of raised funds
（1） Management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange (revised in December 2020) (SZS [2020] No. 1292) and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM (SZS [2022] No. 14) and other relevant laws In accordance with the provisions of laws and regulations and normative documents, and in combination with the actual situation of the company, the measures for the administration of the raised funds of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the “measures”).
According to the management measures, the company implements a special account for the raised funds, establishes a special account for the raised funds in the bank, and together with the sponsor Sinolink Securities Co.Ltd(600109) Co., Ltd., the company and Bank Of Hangzhou Co.Ltd(600926) science and technology sub branch, China Zheshang Bank Co.Ltd(601916) Binjiang sub branch, Hangzhou branch of Tailong commercial bank, China Merchants Bank Co.Ltd(600036) Qiantang sub branch Agricultural Bank Of China Limited(601288) Binjiang sub branch signed the tripartite supervision agreement on raised funds, which defined the rights and obligations of all parties. There is no significant difference between the tripartite supervision agreement and the model tripartite supervision agreement of Shenzhen Stock Exchange, and the company has strictly complied with the raised funds.
（2） Storage of raised funds in special account
As of December 31, 2021, the company has five special accounts for raised funds, and the deposits of raised funds are as follows:
Monetary unit: RMB
Remarks on the balance of raised funds in the account number of the deposit bank
Bank Of Hangzhou Co.Ltd(600926) science and technology sub branch 3 Zhangjiagang Zhonghuan Hailu High-End Equipmentco.Ltd(301040) 1 Jinzhou Port Co.Ltd(600190) 2386365054770804 current deposit
China Zheshang Bank Co.Ltd(601916) Binjiang sub branch 331001013012010014852180045318083 current deposit
Tailong commercial bank Hangzhou 33020010201 Fawer Automotive Parts Limited Company(000030) 95818064972651 current deposit
branch
China Merchants Bank Co.Ltd(600036) Qiantang sub branch 57190891801012319666842498 current deposit
Remarks on the balance of raised funds in the account number of the deposit bank
Agricultural Bank Of China Limited(601288) Binjiang sub branch 19045101040063508 Shanghai Pudong Development Bank Co.Ltd(600000) 000 current deposit
Total 188831904036
3、 Actual use of raised funds this year
（1） Comparison table of use of raised funds
1. See Annex 1 of this report for the comparison table of the use of raised funds.
2. There is no use of over raised funds in this period.
（2） Description of abnormal conditions in the project invested by raised funds
There are no abnormalities in the investment projects of the company with raised funds.
（3） Description of the situation that the benefits of the investment projects with raised funds cannot be calculated separately
The company does not have the situation that the benefits of investment projects with raised funds cannot be calculated separately.
4、 Change the use of funds for investment projects with raised funds
The company does not change the investment projects of raised funds
5、 Problems in the use and disclosure of raised funds
This year, there were no major problems in the use and disclosure of the raised funds of the company.
Attachment: 1 Comparison table of use of raised funds
Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. March 13, 2002 Annex 1
Comparison table of use of raised funds
Year 2021
Prepared by: Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. monetary unit: RMB 10000
Total amount of raised funds 18634301 total amount of raised funds invested in this year
Total amount of raised funds with changed purposes during the reporting period
The accumulated total amount of raised funds with changed purposes has been invested in the total amount of raised funds
Cumulative proportion of total raised funds with changed purposes
Whether the committed investment project has been changed and the raised funds have been adjusted. As of the end of the year, whether the project has reached the scheduled end of the period, whether the project feasibility and the investment of over raised funds in the project (including the total committed investment of the Department, the total investment amount, the cumulative investment amount and the investment progress (%) Benefits realized on the available status date (whether the estimated benefits have changed) (1) (2) (3) = (2) / (1) major changes
1. Committed investment projects Hangzhou Baicheng medical
Pharmaceutical Technology Co., Ltd. no 65051786505178 not applicable
